Applied Filters
LSPN Connect: The battle for COVID-19 vaccines
With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.
SCOTUS won’t resuscitate Amarin’s Vascepa patents
Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.
Bio-Rad asks for review of DNA patent ruling
Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.
UC Berkeley gets $54k for T-cell patent NFT
The University of California Berkeley has sold a non-fungible token based on patent disclosures for Nobel Prize-winning cancer immunotherapies research at an online auction, netting approximately $54,360 from the sale.
No payday for GSK over stolen trade secrets
Two former GlaxoSmithKline researchers do not have to pay restitution for stealing the drugmaker’s trade secrets, a Pennsylvania court has ruled.
Allergan’s Forest to face jury in antitrust suit over Alzheimer drug
Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.
France backs COVID-19 vaccine IP waiver
French President Emmanuel Macron has committed to backing the proposal to waive IP rights for COVID-19 vaccines ahead of the G7 Summit taking place in England this weekend.
Oakwood convinces third circuit to reopen TS suit
Oakwood Laboratories has convinced third circuit judges to revive a trade secrets dispute with its former vice president of product developments over microsphere drugs.
Endo, Impax face class-action over antitrust claims
Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Clarus succeeds in invalidating four Lipocine testosterone patents
Clarus Therapeutics has convinced a US court to invalidate four Lipocine testosterone booster patents it was accused of infringing.
